Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

9.82
-0.0500-0.51%
Post-market: 9.930.1100+1.12%18:48 EDT
Volume:714.95K
Turnover:7.02M
Market Cap:751.41M
PE:-6.82
High:9.95
Open:9.75
Low:9.60
Close:9.87
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.69
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:5.96
PE(LYR):-13.62

Loading ...

Candel Therapeutics to Present NSCLC Aglatimagene Besadenovec Study Data at SITC 2026

Reuters
·
Oct 02

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

GlobeNewswire
·
Oct 02

Candel Therapeutics Grants Inducement Stock Options for 85,900 Shares to Four New Employees

Reuters
·
Oct 02

Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 02

Candel Therapeutics Phase 2a NSCLC Study Shows 24.5-Month Median Overall Survival for Aglatimagene Plus Valacyclovir After ICI Failure

Reuters
·
Oct 01

Candel Therapeutics - 69% of Patients with Multiple Lesions Show Systemic Clinical Response

THOMSON REUTERS
·
Oct 01

Candel Therapeutics - Aglatimagene Plus Valacyclovir Well Tolerated; Grade 3 Adverse Events in 13.7% of Patients

THOMSON REUTERS
·
Oct 01

Candel Therapeutics - Phase 2a Trial Shows Median Overall Survival of 24.5 Months in Nsclc

THOMSON REUTERS
·
Oct 01

Alec Stranahan Reiterates Buy on Candel Therapeutics, Maintains $18 Price Target Amid Advancing Prostate Cancer Program and 2026 BLA Milestone

TIPRANKS
·
Oct 01

Candel Therapeutics Reports Phase 3 Prostate Cancer Biomarker Data Showing Sustained Immune Remodeling After Aglatimagene Treatment

Reuters
·
Sep 30

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at Astro 2026

THOMSON REUTERS
·
Sep 30

Candel Therapeutics Shares Rise After BofA Upgrade

MT Newswires Live
·
Sep 22

H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)

TIPRANKS
·
Sep 22

BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18

MT Newswires Live
·
Sep 21

Candel Therapeutics upgraded to Buy from Neutral at BofA

TIPRANKS
·
Sep 21

Candel Therapeutics CEO Paul Peter Tak Disposes of Common Shares Worth $3,164,815.85

Reuters
·
Sep 12

Candel Therapeutics Director Martine Zimmermann Files Initial Beneficial Ownership Statement

Reuters
·
Sep 11

Candel Therapeutics Adds Independent Director to Board

TIPRANKS
·
Sep 10

Candel Therapeutics Appoints Martine Zimmermann, Pharmd, to Its Board of Directors

THOMSON REUTERS
·
Sep 10